PFIZER INC
CIK 78003 · last filed 2024-08-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$31.05B
Companies
14
Total Filings
26
Lifetime Open-Market Net
$116.74M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | 10%+ Owner | 7,032,770 | $2.94 | $20.64M | $20.00M | 2 | 2023-03-23 |
| Viatris Inc (VTRSV) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2020-11-16 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | 10%+ Owner | 27,349,211 | $18.07 | $494.20M | $12.00M | 1 | 2020-10-29 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | 10%+ Owner | 4,593,847 | $46.99 | $215.86M | $1.80M | 1 | 2019-09-19 |
| Quince Therapeutics, Inc. (CRTX) Delisted | 10%+ Owner | 2,360,071 | $1.95 | $4.60M | $2.55M | 1 | 2019-05-14 |
| ALLO | 10%+ Owner | 21,976,484 | $1.76 | $38.79M | $1.00M | 1 | 2018-10-17 |
| RYTM | 10%+ Owner | 1,387,639 | $106.89 | $148.33M | $680.0K | 1 | 2017-10-10 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,539,224 | — | — | $5.00M | 1 | 2015-10-07 |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 1,135,634 | — | — | -$3.88M | 2 | 2015-08-12 |
| FLXN | 10%+ Owner | 1,452,944 | $24.58 | $35.72M | $0 | 1 | 2014-02-20 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | 10%+ Owner | 119,654 | — | — | $1.82M | 1 | 2014-02-06 |
| ZTS | Director | 400,985,000 | $76.82 | $30.80B | $0 | 2 | 2013-06-26 |
| ICAGEN INC (ICGN) Delisted | 10%+ Owner | 6,393,776 | — | — | $58.16M | 3 | 2011-09-16 |
| ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted | 10%+ Owner | 69,076,466 | — | — | $17.61M | 6 | 2008-04-15 |
Recent Filings · Page 2 of 3
26 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-08-12 | Neurogene Inc. (AQXP) Delisted | Sell (S) | −259,927 | -$6.88M | EDGAR |
| 2014-03-14 | Neurogene Inc. (AQXP) Delisted | Mixed | +1,235,330 | $3.00M | EDGAR |
| 2014-02-20 | FLXN | Conv (C) | +1,687,250 | $0 | EDGAR |
| 2014-02-06 | Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Mixed | +1,794,803 | $2.00M | EDGAR |
| 2013-06-26 | ZTS | Mixed | — | $0 | EDGAR |
| 2013-02-08 | ZTS | Mixed | −86,100,000 | $0 | EDGAR |
| 2011-11-02 | — | Buy (P) | +5,486,538 | $32.92M | |
| 2011-09-16 | ICAGEN INC (ICGN) Delisted | Buy (P) | +464,406 | $2.79M | EDGAR |
| 2011-09-16 | ICAGEN INC (ICGN) Delisted | Buy (P) | +4,611,921 | $27.67M | EDGAR |
| 2011-09-07 | ICAGEN INC (ICGN) Delisted | Buy (P) | +4,617,045 | $27.70M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.